Come and join our amazing team
We are a Swedish biotechnology company founded in 2014 by researchers at the Karolinska Institute
Today we have two business areas with the same core - umbilical cord stem cells
NextCell Pharma focuses on research and development of new stem cell therapies and Cellaviva a tissue establishment approved by IVO and the largest family stem cell biobank in the Nordic region
NextCell’s drug candidate ProTrans represents a platform technology for developing and manufacturing cell therapies to treat autoimmune diseases and inflammatory conditions. We have made the most progress with ProTrans for the treatment of type 1 diabetes, where both safety and efficacy in terms of preserving patients’ ability to produce their own insulin have been demonstrated in multiple clinical drug trials.
In addition to our own clinical trials, ProTrans is also being evaluated in other studies, including an academic study run by Uppsala University in collaboration with Linköping University and Lund University. The aim is to evaluate ProTrans for the treatment of young patients with type 1 diabetes.
The study has been approved and the first patient was included in Q4 2021. Uppsala University is sponsoring the study, which is paid for by research grants. NextCell is contributing ProTrans. The principal investigator is Professor Per-Ola Carlsson and co-investigators are Professor Helena Elding Larsson, Skåne University Hospital and Professor Johnny Ludvigsson, Linköping University Hospital
Cellaviva offers parents
The opportunity to harness their newborn child's stem cells, derived from the umbilical cord after it has been cut, for the child's and family's possible future medical needs
Cellaviva is the only private stem cell bank in Sweden authorised by the Swedish Health Care Inspectorate. Stem cells are now used to treat many serious diseases. Research indicates that cell therapy will also play a significant role in future healthcare and medical treatments. Therefore, we believe that the availability of personal stem cells will be very valuable and are actively working to help expectant parents to save stem cells during childbirth.
Help us to help more families
We are currently expanding our team, in order to meet the growing interest in stem cell collection from families all over the country
There are more and more parents who want to save stem cells, but unfortunately we are not able to send staff to the whole country (as we do in Denmark), so we are now setting up a network of experts in childbirth who, like us, want to help expectant parents have the birth they wish for. This would involve helping with the collection of the material that needs to be sent to the lab, in order to isolate the stem cells (haematopoietic and mesenchymal stem cells).
An example of how it works:
- The family comes into the maternity ward as usual, with a cellaviva box (containing all the medical instruments needed to make a collection of both cord blood and cord tissue).
- Before that, they have been in contact with our on-call service and we in turn with you.
- If you are able to make the collection, you will take over the contact with the family.
- 2 tubes of the mother’s venous blood must be collected, this is most easily made when the IV is inserted from the hospital side, and otherwise when it is convenient.
- The umbilical cord blood is collected immediately after the umbilical cord is clamped and cut (parents decide the time) and the umbilical cord tissue thereafter.
- Everything is packed as instructed, back into the cellaviva box.
- Collection report is written and put in the box.
- The box is sealed and you call our on-call number to say everything is ready, then leave the box with the parents.
- Our on-call staff will book medical transport to the lab.
Do you have any questions or
Would you like to join us?
We are hiring on an ongoing basis so don’t hesitate to get in touch!